FDA Brief

Warning letters Drugs

FDA warning letter to

Hou Fu Biotech - Jiangsu Co., Ltd

High riskIssued Apr 12, 2021Posted Apr 20, 2021Center for Drug Evaluation and Research

Hou Fu Biotech shipped PANROSA hand sanitizer labeled 70% ethanol but tested at 45%, adulterated and misbranded.

What happened

FDA detained and refused admission of a shipment of PANROSA Instant Hand Sanitizer at the U.S. border and tested a batch. The product was labeled 70% ethanol but contained an average of 45% ethanol; FDA also said it was an unapproved new drug and misbranded. On Nov 12, 2020, FDA told the firm by teleconference to consider removing its hand sanitizers from the U.S. market, but no recall had started by the letter date.

What FDA found

  1. The hand sanitizer was labeled to contain 70% ethanol but FDA testing found an average of only 45% ethanol.

    section 501(c) of the FD&C Act, 21 U.S.C. 351(c)
  2. The low ethanol content shows that quality assurance at the facility is not working under CGMP requirements.

    section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)
  3. The hand sanitizer is an unapproved new drug because it is not generally recognized as safe and effective and has no FDA-approved application.

    section 505(a), 21 U.S.C. 355(a); section 301(d), 21 U.S.C. 331(d)
  4. The label is false or misleading because it states a higher ethanol concentration than the product actually contains.

    section 502(a) of the FD&C Act, 21 U.S.C. 352(a)
  5. The label lacks the required warning: “If swallowed, get medical help or contact a Poison Control Center right away.”

    section 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2); 21 CFR 330.1(g)
  6. The product is misbranded because it is a nonprescription drug subject to section 505G but does not meet the requirements for marketing under that section and has no approved application.

    section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)

What FDA wants

FDA asks the firm to respond in writing within 15 working days, including an investigation of the low ethanol content, raw material and supplier lists, all U.S.-shipped batch lists and reconciliation, and complete batch records. FDA also recommends a qualified CGMP consultant and a Regulatory Meeting if the firm wants to manufacture for the U.S. again.

Who should pay attention

  • brands and retailers selling imported hand sanitizer
  • distributors and importers of OTC antiseptic drug products
  • contract manufacturers and suppliers of ethanol-based hand sanitizers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Macau-Union Pharmaceutical Limited

    Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

    High risk
  2. ImprimisRx NJ

    FDA found insanitary sterile compounding and subpotent timolol-latanoprost eye drops at ImprimisRx NJ.

    High risk
  3. Shuzy Rock Inc.

    FDA warns Shuzy Rock Inc. of adulterated hand sanitizers made under insanitary conditions and found below labeled alcohol strength.

    High risk
  4. Guangzhou Zhongkebaishi Health Industry Co., Ltd.

    Guangzhou Zhongkebaishi's Hand Sanitizer Gel, labeled 75% ethanol, tested at 51% and was refused US import.

    High risk